

# Russell E. Lewis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3354394/publications.pdf>

Version: 2024-02-01

283  
papers

18,773  
citations

7568

77  
h-index

16183

124  
g-index

291  
all docs

291  
docs citations

291  
times ranked

13780  
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective. <i>Clinical Infectious Diseases</i> , 2022, 75, 534-544.	5.8	47
2	Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. <i>Lancet Haematology</i> , 2022, 9, e58-e72.	4.6	29
3	Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with <i>Candida</i> spp.. <i>International Journal of Infectious Diseases</i> , 2022, 117, 233-240.	3.3	11
4	Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1290.e1-1290.e4.	6.0	7
5	Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. <i>Lancet Haematology</i> , 2022, 9, e361-e373.	4.6	25
6	Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e3606-e3614.	5.8	335
7	Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?. <i>Lancet Haematology</i> , 2021, 8, e216-e228.	4.6	41
8	Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 217.	3.5	17
9	Navigating the Uncertainties of COVID-19-Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	50
10	Reply to Day et al. <i>Journal of Infectious Diseases</i> , 2021, 224, 1627-1628.	4.0	1
11	Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 288-296.	3.1	7
12	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	8.2	106
13	Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study. <i>Journal of Infection</i> , 2021, 83, 371-380.	3.3	4
14	Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 17.	3.5	36
15	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters. <i>Frontiers in Immunology</i> , 2021, 12, 804988.	4.8	5
16	The timing of plerixafor addition to G-CSF and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 946-954.	2.4	3
17	Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3096-3098.	3.0	1
18	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	4.0	83

#	ARTICLE	IF	CITATIONS
19	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa453.	0.9	7
20	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	8.2	278
21	How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. <i>Clinical Infectious Diseases</i> , 2020, 71, 685-692.	5.8	15
22	Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 1802-1803.	5.8	11
23	Infectious disease consultation for candidaemia. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 164.	9.1	0
24	Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients. <i>Microorganisms</i> , 2020, 8, 2055.	3.6	5
25	<i>Saprochaete clavata</i> infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature. <i>Mycoses</i> , 2019, 62, 1100-1107.	4.0	19
26	Beyond biomarkers: How enhanced CT imaging can improve the diagnostic-driven management of invasive mould disease. <i>Medical Mycology</i> , 2019, 57, S274-S286.	0.7	3
27	Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 114861.	1.8	7
28	Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing <i>Klebsiella pneumoniae</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1925-1931.	2.9	7
29	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
30	Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response. <i>Infection</i> , 2019, 47, 919-927.	4.7	17
31	Live Monitoring and Analysis of Fungal Growth, Viability, and Mycelial Morphology Using the IncuCyte NeuroTrack Processing Module. <i>MBio</i> , 2019, 10, .	4.1	20
32	Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019, 68, S244-S259.	5.8	40
33	Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2019, 68, S260-S274.	5.8	73
34	Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections. <i>Clinical Infectious Diseases</i> , 2019, 68, S241-S243.	5.8	4
35	Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. <i>Journal of Infection</i> , 2019, 78, 484-490.	3.3	20
36	Using State Transition Models To Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	8

#	ARTICLE	IF	CITATIONS
37	Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz505.	0.9	31
38	Preexposure to Isavuconazole Increases the Virulence of <i>Mucorales</i> but Not <i>Aspergillus fumigatus</i> in a <i>Drosophila melanogaster</i> Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	13
39	Extended Infusion of $\beta$ -Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1731-1739.	5.8	29
40	Risk factors for treatment failure in patients receiving $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 574-581.	2.5	3
41	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , 2018, 97, 791-798.	1.8	10
42	Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-sensitive and multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Microbiology and Immunology</i> , 2018, 62, 291-294.	1.4	7
43	Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or <i>Clostridium difficile</i> infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 516-521.	2.5	3
44	The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies. <i>British Journal of Radiology</i> , 2018, 91, 20170220.	2.2	12
45	In vivo evolution of resistant subpopulations of KPC-producing <i>Klebsiella pneumoniae</i> during ceftazidime/avibactam treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1525-1529.	3.0	126
46	Successful treatment of bilateral endogenous <i>Fusarium solani</i> endophthalmitis in a patient with acute lymphocytic leukaemia. <i>Mycoses</i> , 2018, 61, 53-60.	4.0	12
47	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 244-248.	2.5	55
48	Overview of antifungal dosing in invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i33-i43.	3.0	31
49	Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 141.	3.5	7
50	The role of extended infusion $\beta$ -lactams in the treatment of bloodstream infections in patients with liver cirrhosis. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 771-779.	4.4	3
51	Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. <i>Clinical Infectious Diseases</i> , 2018, 67, 1621-1630.	5.8	82
52	Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-centre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2856-2859.	3.0	12
53	Clinical Approach to Infections in the Compromised Host. , 2018, , 1447-1461.		0
54	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 516.	3.5	66

#	ARTICLE	IF	CITATIONS
55	Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment. <i>Transplant Infectious Disease</i> , 2017, 19, e12658.	1.7	12
56	Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	18
57	Changes in In Vitro Susceptibility Patterns of <i>Aspergillus</i> to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015. <i>Clinical Infectious Diseases</i> , 2017, 65, 216-225.	5.8	50
58	In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing <i>Klebsiella pneumoniae</i> clinical isolates. <i>International Journal of Infectious Diseases</i> , 2017, 65, 1-3.	3.3	39
59	Animal Models for Studying Triazole Resistance in <i>Aspergillus fumigatus</i> . <i>Journal of Infectious Diseases</i> , 2017, 216, S466-S473.	4.0	14
60	Radiologic findings of <i>Fusarium</i> pneumonia in neutropenic patients. <i>Mycoses</i> , 2017, 60, 73-78.	4.0	16
61	Using carbapenems for carbapenem-resistant <i>Klebsiella pneumoniae</i> -Are we flogging a dead (work)horse antibiotic?. <i>Virulence</i> , 2017, 8, 13-14.	4.4	1
62	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41.	4.1	62
63	Risk factors for recurrent carbapenem resistant <i>Klebsiella pneumoniae</i> bloodstream infection: a prospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 1965-1970.	2.9	17
64	Preface. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, ii1-ii1.	3.0	0
65	Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of <i>Rhizopus oryzae</i> . <i>Journal of Infectious Diseases</i> , 2016, 214, 114-121.	4.0	30
66	Improved Radiographic Imaging of Invasive Fungal Disease: The Cornerstone to Antifungal Stewardship in the Hematology Units?. <i>Current Fungal Infection Reports</i> , 2016, 10, 78-86.	2.6	6
67	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1914-1921.	7.0	110
68	Bloodstream infections in patients with liver cirrhosis. <i>Virulence</i> , 2016, 7, 309-319.	4.4	67
69	Mucorales-Specific T Cells in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2016, 11, e0149108.	2.5	40
70	High-dose Weekly Liposomal Amphotericin B Antifungal Prophylaxis in Patients Undergoing Liver Transplantation. <i>Transplantation</i> , 2015, 99, 848-854.	1.0	23
71	Agents of Mucormycosis and Entomophthoromycosis. , 2015, , 2909-2919.e3.		11
72	Risk Factors for Infection With Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>American Journal of Transplantation</i> , 2015, 15, 1708-1715.	4.7	99

#	ARTICLE	IF	CITATIONS
73	Antifungal Agents. , 2015, , 79-97.		1
74	Effect of Preexposure to Triazoles on Susceptibility and Virulence of <i>Rhizopus oryzae</i> . Antimicrobial Agents and Chemotherapy, 2015, 59, 7830-7832.	3.2	9
75	Serum Galactomannan Diagnosis of Breakthrough Invasive Fungal Disease. Clinical Infectious Diseases, 2015, 60, 1284-1284.	5.8	2
76	Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians. Current Opinion in Pharmacology, 2015, 24, 30-37.	3.5	39
77	Innate Inflammatory Response and Immunopharmacologic Activity of Micafungin, Caspofungin, and Voriconazole against Wild-Type and <i>FKS</i> Mutant <i>Candida glabrata</i> Isolates. Antimicrobial Agents and Chemotherapy, 2015, 59, 5405-5412.	3.2	11
78	Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis. Annals of Pharmacotherapy, 2015, 49, 978-985.	1.9	9
79	High Resolution Computed Tomography Angiography Improves the Radiographic Diagnosis of Invasive Mold Disease in Patients With Hematological Malignancies. Clinical Infectious Diseases, 2015, 60, 1603-1610.	5.8	83
80	Computerized tomographic pulmonary angiography discriminates invasive mould disease of the lung from lymphoma. British Journal of Haematology, 2015, 169, 462-462.	2.5	2
81	Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum $\beta$ -Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae. Infectious Diseases and Therapy, 2015, 4, 65-83.	4.0	40
82	Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clinical Microbiology and Infection, 2015, 21, 242-247.	6.0	63
83	Treatment Principles for the Management of Mold Infections. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a019737-a019737.	6.2	18
84	Reply to "Risk for Invasive Fungal Infections during Acute Myeloid Leukemia Induction Therapy: a True Association with Echinocandins?". Antimicrobial Agents and Chemotherapy, 2014, 58, 4990-4991.	3.2	0
85	<i>Klebsiella pneumoniae</i> Bloodstream Infection. Medicine (United States), 2014, 93, 298-309.	1.0	100
86	Anidulafungin versus Caspofungin in a Mouse Model of Candidiasis Caused by Anidulafungin-Susceptible <i>Candida parapsilosis</i> Isolates with Different Degrees of Caspofungin Susceptibility. Antimicrobial Agents and Chemotherapy, 2014, 58, 229-236.	3.2	11
87	Risk factors for carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection among rectal carriers: a prospective observational multicentre study. Clinical Microbiology and Infection, 2014, 20, 1357-1362.	6.0	182
88	Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6767-6772.	3.2	42
89	Different Recommendations for Daptomycin Dosing Over Time in Patients With Severe Infections. Clinical Infectious Diseases, 2014, 58, 1788-1789.	5.8	13
90	Macrophage Reporter Cell Assay for Screening Immunopharmacological Activity of Cell Wall-Active Antifungals. Antimicrobial Agents and Chemotherapy, 2014, 58, 1738-1743.	3.2	16

#	ARTICLE	IF	CITATIONS
91	In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing <i>Klebsiella pneumoniae</i> bloodstream isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1856-1865.	3.0	71
92	Oral Gentamicin Gut Decontamination for Prevention of KPC-Producing <i>Klebsiella pneumoniae</i> Infections: Relevance of Concomitant Systemic Antibiotic Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1972-1976.	3.2	55
93	Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. <i>Mycoses</i> , 2014, 57, 49-55.	4.0	25
94	Carbapenem-resistant <i>Klebsiella pneumoniae</i> colonization at liver transplantation: A management challenge. <i>Liver Transplantation</i> , 2014, 20, 631-633.	2.4	7
95	Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 51-58.	3.7	104
96	Effectiveness of Primary Anti-Aspergillus Prophylaxis during Remission Induction Chemotherapy of Acute Myeloid Leukemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2775-2780.	3.2	39
97	Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Patients in a Tertiary Cancer Center, 2009 to 2011. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 865-873.	3.2	49
98	Immunomodulatory Agents as Adjunctive Therapy for the Treatment of Resistant <i>Candida</i> Species. <i>Current Fungal Infection Reports</i> , 2013, 7, 119-125.	2.6	2
99	Routine use of a real-time polymerase chain reaction method for detection of bloodstream infections in neutropaenic patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 130-134.	1.8	35
100	Epidemiology and treatment of mucormycosis. <i>Future Microbiology</i> , 2013, 8, 1163-1175.	2.0	89
101	Predictors of mortality in multidrug-resistant <i>Klebsiella pneumoniae</i> bloodstream infections. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 1053-1063.	4.4	82
102	Aggressive versus conservative initiation of antibiotics. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 387.	9.1	2
103	Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1730-1733.	1.3	31
104	Treatment of carbapenem-resistant <i>Klebsiella pneumoniae</i> : the state of the art. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 159-177.	4.4	139
105	<i>Drosophila melanogaster</i> as a model to explore the effects of methicillin-resistant <i>Staphylococcus aureus</i> strain type on virulence and response to linezolid treatment. <i>Microbial Pathogenesis</i> , 2013, 55, 16-20.	2.9	9
106	The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. <i>Bone Marrow Transplantation</i> , 2013, 48, 141-143.	2.4	14
107	Tacrolimus Enhances the Potency of Posaconazole Against <i>Rhizopus oryzae</i> In Vitro and in an Experimental Model of Mucormycosis. <i>Journal of Infectious Diseases</i> , 2013, 207, 834-841.	4.0	55
108	Proangiogenic Growth Factors Potentiate In Situ Angiogenesis and Enhance Antifungal Drug Activity in Murine Invasive Aspergillosis. <i>Journal of Infectious Diseases</i> , 2013, 207, 1066-1074.	4.0	22

#	ARTICLE	IF	CITATIONS
109	Synergistic Activity of Colistin plus Rifampin against Colistin-Resistant KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3990-3993.	3.2	99
110	High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental <i>Aspergillus terreus</i> pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1148-1151.	3.0	9
111	Hyperthermia Sensitizes <i>Rhizopus oryzae</i> to Posaconazole and Itraconazole Action through Apoptosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4360-4368.	3.2	16
112	Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. <i>Mycoses</i> , 2013, 56, 638-645.	4.0	198
113	A Risk Prediction Score for Invasive Mold Disease in Patients with Hematological Malignancies. <i>PLoS ONE</i> , 2013, 8, e75531.	2.5	51
114	How Does Antifungal Pharmacology Differ for Mucormycosis Versus Aspergillosis?. <i>Clinical Infectious Diseases</i> , 2012, 54, S67-S72.	5.8	51
115	Importance of Pharmacokinetic Considerations for Selecting Therapy in the Treatment of Invasive Fungal Infections. <i>American Journal of Therapeutics</i> , 2012, 19, 51-63.	0.9	8
116	Computed Tomographic Pulmonary Angiography for Diagnosis of Invasive Mold Diseases in Patients With Hematological Malignancies. <i>Clinical Infectious Diseases</i> , 2012, 54, 610-616.	5.8	57
117	Combination Therapy for Mucormycosis: Why, What, and How?. <i>Clinical Infectious Diseases</i> , 2012, 54, S73-S78.	5.8	139
118	Future Directions in Mucormycosis Research. <i>Clinical Infectious Diseases</i> , 2012, 54, S79-S85.	5.8	42
119	Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 422-429.	3.0	5
120	Mouse models for the study of fungal pneumonia. <i>Virulence</i> , 2012, 3, 329-338.	4.4	16
121	The potential impact of antifungal drug resistance mechanisms on the host immune response to <i>Candida</i> . <i>Virulence</i> , 2012, 3, 368-376.	4.4	38
122	Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies. <i>Medical Mycology</i> , 2012, 50, 543-548.	0.7	18
123	Invasive Mold Infections in Pediatric Cancer Patients Reflect Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year, Single-Institution, Retrospective Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2012, 1, 125-135.	1.3	29
124	Echinocandin Resistance in <i>Candida</i> Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1086-1096.	1.9	87
125	Interactions of Liposome Carriers with Infectious Fungal Hyphae Reveals the Role of $\beta$ -Glucans. <i>Molecular Pharmaceutics</i> , 2012, 9, 2489-2496.	4.6	9
126	Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses. <i>Current Fungal Infection Reports</i> , 2012, 6, 349-357.	2.6	3



#	ARTICLE	IF	CITATIONS
127	Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. <i>Journal of Infection</i> , 2012, 64, 68-75.	3.3	124
128	Current Concepts in Antifungal Pharmacology. <i>Mayo Clinic Proceedings</i> , 2011, 86, 805-817.	3.0	305
129	Pharmacokineticâ€“pharmacodynamic optimization of triazole antifungal therapy. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, S14-S29.	3.1	10
130	How I treat mucormycosis. <i>Blood</i> , 2011, 118, 1216-1224.	1.4	282
131	<i>In vitro</i> interactions among echinocandins against <i>Aspergillus fumigatus</i> : lack of concordance among methods. <i>Medical Mycology</i> , 2011, 49, 285-288.	0.7	8
132	Cutaneous Mucormycosis in Tornado Survivors. <i>Current Fungal Infection Reports</i> , 2011, 5, 187-189.	2.6	2
133	Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of <i>Aspergillus fumigatus</i> - <i>Rhizopus oryzae</i> pulmonary infection. <i>Virulence</i> , 2011, 2, 348-355.	4.4	46
134	Efficacy of Caspofungin in Neutropenic and Corticosteroid-Immunosuppressed Murine Models of Invasive Pulmonary Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3584-3587.	3.2	11
135	Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of <i>Candida</i> and <i>Aspergillus</i> species. <i>Virulence</i> , 2011, 2, 280-295.	4.4	31
136	Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species. <i>Clinical Microbiology Reviews</i> , 2011, 24, 411-445.	13.6	340
137	Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1324-1331.	3.0	16
138	Activity of Deferasirox in <i>Mucorales</i> : Influences of Species and Exogenous Iron. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 411-413.	3.2	24
139	Fitness and Virulence Costs of <i>Candida albicans</i> FKS1 Hot Spot Mutations Associated With Echinocandin Resistance. <i>Journal of Infectious Diseases</i> , 2011, 204, 626-635.	4.0	124
140	Fungal Drug Resistance and Pharmacologic Considerations of Dosing Newer Antifungal Therapies. , 2011, , 317-329.		0
141	Fungal Infections in Leukemia Patients: How Do We Prevent and Treat Them?. <i>Clinical Infectious Diseases</i> , 2010, 50, 405-415.	5.8	125
142	Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998â€“2009. <i>Journal of Infection</i> , 2010, 60, 331-337.	3.3	145
143	Antifungal Therapeutic Drug Monitoring. <i>Current Fungal Infection Reports</i> , 2010, 4, 158-167.	2.6	24
144	Enemy of the (immunosuppressed) state: an update on the pathogenesis of <i>Aspergillus fumigatus</i> infection. <i>British Journal of Haematology</i> , 2010, 150, 406-417.	2.5	111

#	ARTICLE	IF	CITATIONS
145	Caspofungin-non-susceptible <i>Candida</i> isolates in cancer patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 293-295.	3.0	37
146	Antifungal Activity of Colistin against <i>Mucorales</i> Species <i>In Vitro</i> and in a Murine Model of <i>Rhizopus oryzae</i> Pulmonary Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 484-490.	3.2	56
147	Interstrain variability in the virulence of <i>Aspergillus fumigatus</i> and <i>Aspergillus terreus</i> in a <i>Toll</i> -deficient <i>Drosophila</i> fly model of invasive aspergillosis. <i>Medical Mycology</i> , 2010, 48, 310-317.	0.7	32
148	Cutaneous Model of Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1848-1854.	3.2	31
149	Exploring the concordance of <i>Aspergillus fumigatus</i> pathogenicity in mice and <i>Toll</i> -deficient flies. <i>Medical Mycology</i> , 2010, 48, 506-510.	0.7	27
150	Comparative Pharmacodynamics of Amphotericin B Lipid Complex and Liposomal Amphotericin B in a Murine Model of Pulmonary Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1298-1304.	3.2	69
151	Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. <i>Medical Mycology</i> , 2010, 48, 817-823.	0.7	36
152	<i>Toll</i> -deficient <i>Drosophila</i> are resistant to infection by <i>Pneumocystis</i> spp.: additional evidence of specificity to mammalian hosts. <i>Virulence</i> , 2010, 1, 523-525.	4.4	6
153	Stimulated Innate Resistance of Lung Epithelium Protects Mice Broadly against Bacteria and Fungi. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010, 42, 40-50.	2.9	100
154	Characterization of a 5-azacytidine-induced developmental <i>Aspergillus fumigatus</i> variant. <i>Virulence</i> , 2010, 1, 164-173.	4.4	19
155	Lack of galactomannan reactivity in dematiaceous molds recovered from cancer patients with phaeohyphomycosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 200-203.	1.8	11
156	Agents of Mucormycosis and Entomophthoromycosis. , 2010, , 3257-3269.		22
157	Interstrain variability in the virulence of <i>Aspergillus fumigatus</i> and <i>Aspergillus terreus</i> in a <i>Toll</i> -deficient <i>Drosophila</i> fly model of invasive aspergillosis. <i>Medical Mycology</i> , 2010, 48, 1-9.	0.7	17
158	Antifungal activity against <i>Scedosporium</i> species and novel assays to assess antifungal pharmacodynamics against filamentous fungi. <i>Medical Mycology</i> , 2009, 47, 422-432.	0.7	34
159	Invasive aspergillosis in glucocorticoid-treated patients. <i>Medical Mycology</i> , 2009, 47, S271-S281.	0.7	100
160	Phaeohyphomycosis in a Tertiary Care Cancer Center. <i>Clinical Infectious Diseases</i> , 2009, 48, 1033-1041.	5.8	116
161	<i>Candida albicans</i> Cas5, a Regulator of Cell Wall Integrity, Is Required for Virulence in Murine and <i>Toll</i> Mutant Fly Models. <i>Journal of Infectious Diseases</i> , 2009, 200, 152-157.	4.0	43
162	Increased Virulence of Zygomycetes Organisms Following Exposure to Voriconazole: A Study Involving Fly and Murine Models of Zygomycosis. <i>Journal of Infectious Diseases</i> , 2009, 199, 1399-1406.	4.0	117

#	ARTICLE	IF	CITATIONS
163	Culture Medium Composition Affects the Lethality of <i>Cunninghamella bertholletiae</i> in a Fly Model of Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4569-4569.	3.2	11
164	Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007). <i>Cancer</i> , 2009, 115, 4745-4752.	4.1	236
165	Immunomodulating effects of antifungal therapy. <i>Current Fungal Infection Reports</i> , 2009, 3, 243-250.	2.6	3
166	Azoles and antidepressants: a mini-review of the tolerability of co-administration. <i>Mycoses</i> , 2009, 52, 433-439.	4.0	4
167	Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. <i>Clinical Microbiology and Infection</i> , 2009, 15, 93-97.	6.0	106
168	A clinicopathological study of pulmonary mucormycosis in cancer patients: Extensive angioinvasion but limited inflammatory response. <i>Journal of Infection</i> , 2009, 59, 134-138.	3.3	88
169	Increased bacterial adherence and biomass in <i>Pseudomonas aeruginosa</i> bacteria exposed to clarithromycin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 81-86.	1.8	15
170	In vivo dynamics of carbapenem-resistant <i>Pseudomonas aeruginosa</i> selection after suboptimal dosing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 427-433.	1.8	17
171	The Burden of Bacterial and Viral Infections in Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 128-133.	2.0	19
172	Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 95-98.	2.5	16
173	Supplement: Trends in invasive <i>Candida</i> infections and their treatment: focus on echinocandins. <i>Current Medical Research and Opinion</i> , 2009, 25, 1729-1762.	1.9	74
174	<i>Aspergillus fumigatus</i> inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. <i>Blood</i> , 2009, 114, 5393-5399.	1.4	99
175	Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 376-384.	3.1	31
176	Polyene Antifungal Agents. , 2009, , 281-305.		0
177	Pharmacokinetic considerations for the use of newer antifungal agents. <i>Current Fungal Infection Reports</i> , 2008, 2, 5-11.	2.6	0
178	Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2008, 27, 343-347.	2.9	54
179	<i>Candida lusitanae</i> fungemia in cancer patients: risk factors for amphotericin B failure and outcome. <i>Medical Mycology</i> , 2008, 46, 541-546.	0.7	83
180	What Is the "Therapeutic Range" for Voriconazole?. <i>Clinical Infectious Diseases</i> , 2008, 46, 212-214.	5.8	45

#	ARTICLE	IF	CITATIONS
181	Efficacy of Single-Dose Liposomal Amphotericin B or Micafungin Prophylaxis in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4178-4180.	3.2	22
182	Immunocompromised Hosts: Immunopharmacology of Modern Antifungals. <i>Clinical Infectious Diseases</i> , 2008, 47, 226-235.	5.8	125
183	Does pre-exposure of <i>Aspergillus fumigatus</i> to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 539-542.	3.0	15
184	<i>Zygomycetes</i> Hyphae Trigger an Early, Robust Proinflammatory Response in Human Polymorphonuclear Neutrophils through Toll-Like Receptor 2 Induction but Display Relative Resistance to Oxidative Damage. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 722-724.	3.2	86
185	Caspofungin-Resistant <i>Candida tropicalis</i> Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4181-4183.	3.2	119
186	Delaying Amphotericin B-Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis. <i>Clinical Infectious Diseases</i> , 2008, 47, 503-509.	5.8	639
187	Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1140-1144.	3.0	57
188	Caspofungin-Mediated $\beta$ -Glucan Unmasking and Enhancement of Human Polymorphonuclear Neutrophil Activity against <i>Aspergillus</i> and Non- <i>Aspergillus</i> Hyphae. <i>Journal of Infectious Diseases</i> , 2008, 198, 186-192.	4.0	174
189	Genomewide Screening for Genes Associated with Gliotoxin Resistance and Sensitivity in <i>Saccharomyces cerevisiae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1325-1329.	3.2	11
190	Calcineurin Inhibitor Agents Interact Synergistically with Antifungal Agents In Vitro against <i>Cryptococcus neoformans</i> Isolates: Correlation with Outcome in Solid Organ Transplant Recipients with Cryptococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 735-738.	3.2	91
191	<i>Drosophila melanogaster</i> as a model host to dissect the immunopathogenesis of zygomycosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9367-9372.	7.1	123
192	Paradoxical Effect of Echinocandins across <i>Candida</i> Species In Vitro: Evidence for Echinocandin-Specific and <i>Candida</i> Species-Related Differences. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2257-2259.	3.2	160
193	Effects of <i>Aspergillus fumigatus</i> gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. <i>Journal of Leukocyte Biology</i> , 2007, 82, 839-848.	3.3	61
194	Posaconazole Prophylaxis in Hematologic Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 2214-2218.	27.0	10
195	Increased Culture Recovery of <i>Zygomycetes</i> Under Physiologic Temperature Conditions. <i>American Journal of Clinical Pathology</i> , 2007, 127, 208-212.	0.7	48
196	Pretreatment with Empty Liposomes Attenuates the Immunopathology of Invasive Pulmonary Aspergillosis in Corticosteroid-Immunosuppressed Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1078-1081.	3.2	45
197	Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1253-1258.	3.2	64
198	Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis. <i>Fungal Genetics and Biology</i> , 2007, 44, 88-92.	2.1	13

#	ARTICLE	IF	CITATIONS
199	Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: A retrospective, nonrandomized autopsy study. <i>Clinical Therapeutics</i> , 2007, 29, 1980-1986.	2.5	31
200	Pharmacodynamic implications for use of antifungal agents. <i>Current Opinion in Pharmacology</i> , 2007, 7, 491-497.	3.5	33
201	Role of mini-host models in the study of medically important fungi. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 42-55.	9.1	81
202	Virulence Studies of <i>Scedosporium</i> and <i>Fusarium</i> Species in <i>Drosophila melanogaster</i> . <i>Journal of Infectious Diseases</i> , 2007, 196, 1860-1864.	4.0	39
203	Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. <i>Cancer</i> , 2007, 110, 1303-1306.	4.1	148
204	Caspofungin as Primary Antifungal Prophylaxis in Stem Cell Transplant Recipients. <i>Pharmacotherapy</i> , 2007, 27, 1644-1650.	2.6	69
205	Random plasma concentrations of voriconazole decline over time. <i>Journal of Infection</i> , 2007, 55, e129-e130.	3.3	27
206	Posaconazole prophylaxis in hematologic cancer. <i>New England Journal of Medicine</i> , 2007, 356, 2214-5; author reply 2215-8.	27.0	2
207	Invasive Zygomycosis: Update on Pathogenesis, Clinical Manifestations, and Management. <i>Infectious Disease Clinics of North America</i> , 2006, 20, 581-607.	5.1	219
208	<i>Drosophila melanogaster</i> as a Facile Model for Large-Scale Studies of Virulence Mechanisms and Antifungal Drug Efficacy in <i>Candida</i> Species. <i>Journal of Infectious Diseases</i> , 2006, 193, 1014-1022.	4.0	105
209	Pharmacology of Systemic Antifungal Agents. <i>Clinical Infectious Diseases</i> , 2006, 43, S28-S39.	5.8	253
210	Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 96-103.	3.2	112
211	Judgments of Value, Judgments of Fact: The Ethical Dimension of Biohistorical Research. <i>Public Historian</i> , 2006, 28, 93-99.	0.0	2
212	Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. <i>Mycoses</i> , 2006, 49, 226-231.	4.0	28
213	Decision Making in Antifungal Monotherapy versus Combination Therapy. <i>Pharmacotherapy</i> , 2006, 26, 61S-67S.	2.6	11
214	Pentamidine Is Active in a Neutropenic Murine Model of Acute Invasive Pulmonary Fusariosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 294-297.	3.2	10
215	In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against <i>Candida</i> species in the presence of human serum albumin. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 288-293.	3.0	22
216	Managing drug interactions in the patient with aspergillosis. <i>Medical Mycology</i> , 2006, 44, 349-356.	0.7	49

#	ARTICLE	IF	CITATIONS
217	Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 469-473.	3.2	92
218	Combination of Voriconazole and Caspofungin as Primary Therapy for Invasive Aspergillosis in Solid Organ Transplant Recipients: A Prospective, Multicenter, Observational Study. <i>Transplantation</i> , 2006, 81, 320-326.	1.0	297
219	<i>Scedosporium</i> Infection in a Tertiary Care Cancer Center: A Review of 25 Cases from 1989-2006. <i>Clinical Infectious Diseases</i> , 2006, 43, 1580-1584.	5.8	155
220	Effect of Amphotericin B and Micafungin Combination on Survival, Histopathology, and Fungal Burden in Experimental Aspergillosis in the p47 <sup>&lt;i&gt;phox&lt;/i&gt;</sup> <sup>&lt;sup&gt;â&lt;/sup&gt;</sup> Mouse Model of Chronic Granulomatous Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 422-427.	3.2	66
221	Inhibition of <i>Candida parapsilosis</i> Mitochondrial Respiratory Pathways Enhances Susceptibility to Caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 744-747.	3.2	38
222	Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). <i>Haematologica</i> , 2006, 91, 986-9.	3.5	357
223	<i>Aspergillus fumigatus</i> suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. <i>Blood</i> , 2005, 105, 2258-2265.	1.4	183
224	<i>Aspergillus</i> Susceptibility Testing in Patients with Cancer and Invasive Aspergillosis: Difficulties in Establishing Correlation Between In Vitro Susceptibility Data and the Outcome of Initial Amphotericin B Therapy. <i>Pharmacotherapy</i> , 2005, 25, 1174-1180.	2.6	36
225	Tollâ€Deficient <i>Drosophila</i> Flies as a Fast, Highâ€Throughput Model for the Study of Antifungal Drug Efficacy against Invasive Aspergillosis and <i>Aspergillus</i> Virulence. <i>Journal of Infectious Diseases</i> , 2005, 191, 1188-1195.	4.0	84
226	Micafungin in combination with voriconazole in <i>Aspergillus</i> species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 887-892.	3.0	33
227	Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 792-795.	3.0	47
228	Predictors of Pulmonary Zygomycosis versus Invasive Pulmonary Aspergillosis in Patients with Cancer. <i>Clinical Infectious Diseases</i> , 2005, 41, 60-66.	5.8	322
229	Attenuation of the Activity of Caspofungin at High Concentrations against <i>Candida albicans</i> : Possible Role of Cell Wall Integrity and Calcineurin Pathways. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 5146-5148.	3.2	127
230	Development of a Ligand-Directed Approach To Study the Pathogenesis of Invasive Aspergillosis. <i>Infection and Immunity</i> , 2005, 73, 7747-7758.	2.2	13
231	Caspofungin versus Liposomal Amphotericin B for Empirical Therapy. <i>New England Journal of Medicine</i> , 2005, 352, 410-414.	27.0	13
232	Frequency and Species Distribution of Gliotoxin-Producing <i>Aspergillus</i> Isolates Recovered from Patients at a Tertiary-Care Cancer Center. <i>Journal of Clinical Microbiology</i> , 2005, 43, 6120-6122.	3.9	99
233	Zygomycosis in a Tertiaryâ€Care Cancer Center in the Era of <i>Aspergillus</i> â€Active Antifungal Therapy: A Caseâ€Control Observational Study of 27 Recent Cases. <i>Journal of Infectious Diseases</i> , 2005, 191, 1350-1360.	4.0	659
234	In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against <i>Aspergillus</i> , <i>Fusarium</i> , and <i>Scedosporium</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 945-951.	3.2	111

#	ARTICLE	IF	CITATIONS
235	Vancomycin-Resistant <i>Enterococcus faecium</i> : Catheter Colonization, esp Gene, and Decreased Susceptibility to Antibiotics in Biofilm. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 5046-5050.	3.2	55
236	Detection of Gliotoxin in Experimental and Human Aspergillosis. <i>Infection and Immunity</i> , 2005, 73, 635-637.	2.2	171
237	Pharmacodynamics of Polymyxin B against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3624-3630.	3.2	198
238	Increased frequency of non-fumigatus <i>Aspergillus</i> species in amphotericin B or triazole pre-exposed cancer patients with positive cultures for aspergilli. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 15-20.	1.8	78
239	Murine Model of Invasive Aspergillosis. , 2005, 118, 129-142.		24
240	ETHICS: Enhanced: Constructing Ethical Guidelines for Biohistory. <i>Science</i> , 2004, 304, 215-216.	12.6	17
241	Novel Approach to Characterization of Combined Pharmacodynamic Effects of Antimicrobial Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4315-4321.	3.2	34
242	Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of <i>Candida albicans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 376-385.	3.0	100
243	Pharmacodynamics of Caspofungin in a Murine Model of Invasive Pulmonary Aspergillosis: Evidence of Concentration-Dependent Activity. <i>Journal of Infectious Diseases</i> , 2004, 190, 1464-1471.	4.0	195
244	Challenges in Designing Animal Studies To Detect Antagonism of Polyene Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3211-3212.	3.2	1
245	Extra Copies of the <i>Aspergillus fumigatus</i> Squalene Epoxidase Gene Confer Resistance to Terbinafine: Genetic Approach to Studying Gene Dose-Dependent Resistance to Antifungals in <i>A. fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2490-2496.	3.2	52
246	Toward more effective antifungal therapy: the prospects of combination therapy. <i>British Journal of Haematology</i> , 2004, 126, 165-175.	2.5	75
247	Screening of Antibacterial and Antifungal Activities of Ten Medicinal Plants from Ghana. <i>Pharmaceutical Biology</i> , 2004, 42, 13-17.	2.9	26
248	Invasive Aspergillosis in Patients with Hematologic Malignancies. <i>Pharmacotherapy</i> , 2003, 23, 1592-1610.	2.6	49
249	Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. <i>Cancer</i> , 2003, 98, 292-299.	4.1	279
250	Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. <i>Drug Resistance Updates</i> , 2003, 6, 257-269.	14.4	57
251	Aspergillosis caused by non-fumigatus <i>Aspergillus</i> species: risk factors and in vitro susceptibility compared with <i>Aspergillus fumigatus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 46, 25-28.	1.8	57
252	Sequential exposure of <i>Aspergillus fumigatus</i> to itraconazole and caspofungin: evidence of enhanced in vitro activity. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 47, 415-419.	1.8	19

#	ARTICLE	IF	CITATIONS
253	The activity of amphotericin B against <i>Candida albicans</i> is not directly associated with extracellular calcium concentration. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 305-312.	3.0	4
254	Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in <i>Aspergillus</i> species. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 313-316.	3.0	110
255	The Solubility Ceiling: A Rationale for Continuous Infusion Amphotericin B Therapy?. <i>Clinical Infectious Diseases</i> , 2003, 37, 871-872.	5.8	46
256	Pentamidine Is Active In Vitro against <i>Fusarium</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3252-3259.	3.2	25
257	The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1313-1333.	4.1	130
258	Attenuation of Itraconazole Fungicidal Activity following Preexposure of <i>Aspergillus fumigatus</i> to Fluconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3592-3597.	3.2	18
259	Candidemia in a Tertiary Care Cancer Center. <i>Medicine (United States)</i> , 2003, 82, 309-321.	1.0	113
260	Pharmacotherapy of <i>Candida</i> bloodstream infections: new treatment options, new era. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1039-1057.	1.8	7
261	Lack of Catheter Infection by the <i>efg1 / efg1 cph1 / cph1</i> Double-Null Mutant, a <i>Candida albicans</i> Strain That Is Defective in Filamentous Growth. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1153-1155.	3.2	62
262	Antifungal Activity of Amphotericin B, Fluconazole, and Voriconazole in an In Vitro Model of <i>Candida</i> Catheter-Related Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3499-3505.	3.2	93
263	Pulmonary Candidiasis in Patients with Cancer: An Autopsy Study. <i>Clinical Infectious Diseases</i> , 2002, 34, 400-403.	5.8	98
264	Itraconazole Preexposure Attenuates the Efficacy of Subsequent Amphotericin B Therapy in a Murine Model of Acute Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3208-3214.	3.2	88
265	Antifungal drug resistance of pathogenic fungi. <i>Lancet, The</i> , 2002, 359, 1135-1144.	13.7	380
266	Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against <i>Candida</i> spp. and <i>Cryptococcus neoformans</i> via time-kill methods. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 43, 13-17.	1.8	94
267	<i>Aspergillus nidulans</i> frequently resistant to amphotericin B. <i>Mycoses</i> , 2002, 45, 406-407.	4.0	72
268	Evaluation of amphotericin B and flucytosine in combination against <i>Candida albicans</i> and <i>Cryptococcus neoformans</i> using time-kill methodology. <i>Diagnostic Microbiology and Infectious Disease</i> , 2001, 41, 121-126.	1.8	36
269	Rationale for Combination Antifungal Therapy. <i>Pharmacotherapy</i> , 2001, 21, 149S-164S.	2.6	95
270	Progressive Disseminated Aspergillosis in a Bone Marrow Transplant Recipient: Response with a High-Dose Lipid Formulation of Amphotericin B. <i>Clinical Infectious Diseases</i> , 2001, 32, e94-e96.	5.8	13



#	ARTICLE	IF	CITATIONS
271	Candida Lusitaniae Catheter-Related Sepsis. <i>Annals of Pharmacotherapy</i> , 2001, 35, 1570-1574.	1.9	15
272	Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1917-1920.	3.2	101
273	Itraconazole-Amphotericin B Antagonism in <i>Aspergillus fumigatus</i> : an E-Test-Based Strategy. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2915-2918.	3.2	72
274	Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against <i>Bacteroides</i> spp. using an in vitro model of infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2000, 37, 51-55.	1.8	13
275	In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods†. <i>Diagnostic Microbiology and Infectious Disease</i> , 2000, 36, 101-105.	1.8	40
276	Evaluation of Low-Dose, Extended-Interval Clindamycin Regimens against <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> Using a Dynamic In Vitro Model of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2005-2009.	3.2	19
277	The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. <i>American Journal of Health-System Pharmacy</i> , 1999, 56, 525-533.	1.0	37
278	Therapy of Candidal Infections: Susceptibility Testing, Resistance, and Therapeutic Options. <i>Annals of Pharmacotherapy</i> , 1998, 32, 1353-1361.	1.9	20
279	Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 1207-1212.	3.2	260
280	Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination against <i>Candida albicans</i> by Using a Dynamic In Vitro Mycotic Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 1382-1386.	3.2	87
281	Combination Systemic Antifungal Therapy for Cryptococcosis, Candidiasis, and Aspergillosis. <i>Journal of Public Health Pharmacy</i> , 1998, 3, 61-84.	0.1	18
282	The Impact of Antifungal Drug Resistance in the Clinic. , 0, , 373-385.		1
283	Antifungal Drug Interactions. , 0, , 445-456.		1